Navigation Links
Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors

AURORA, Colo., Nov. 15, 2011 /PRNewswire/ -- In a strategic effort to refocus and strengthen its organization, the Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the direction, roles, responsibilities and allocation of resources going forward. The announcement is made by Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our board of directors with four of the area's most well-known and successful leaders in the bioscience industry."

Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP;  and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.

Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board."

Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Fruend Investments; and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials to be named by the Aurora City Council.

About Fitzsimons Redevelopment Authority

The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner, Forest City Science + Technology Group. Visit:

SOURCE Fitzsimons Redevelopment Authority
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
3. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
4. Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
5. Kansas Bioscience Authority Commits $50 Million to Increase Venture Capital, Accelerate Bioscience Business Growth
6. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
7. Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority
8. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
9. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
10. Rice rolls out new nanocars
Post Your Comments:
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: ... area for financial services, but it also plays a fundamental ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):